The first time I highlighted a simple covered call strategy around mid-cap biotech concern BioMarin Pharmaceuticals (BMRN) was in late August 2020 (read it here). The stock has just dropped some 40% to $75 a share after the FDA slapped a complete response letter (CRL) on its application for its gene therapy known under the brand name RockavianThe...
Read the full story and get access to the Real Money Pro trading floor.
There's no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.